See more : Infratil Limited (IFUUF) Income Statement Analysis – Financial Results
Complete financial analysis of Concert Pharmaceuticals, Inc. (CNCE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Concert Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Thinkon Semiconductor Jinzhou Corp. (688233.SS) Income Statement Analysis – Financial Results
- Alembic Limited (ALEMBICLTD.BO) Income Statement Analysis – Financial Results
- PT Wahana Interfood Nusantara Tbk (COCO.JK) Income Statement Analysis – Financial Results
- Gencell Ltd (GNCL.TA) Income Statement Analysis – Financial Results
- Lian Hwa Foods Corporation (1231.TW) Income Statement Analysis – Financial Results
Concert Pharmaceuticals, Inc. (CNCE)
About Concert Pharmaceuticals, Inc.
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32.58M | 7.90M | 1.08M | 10.51M | 143.89M | 174.00K | 66.73M | 8.58M | 25.41M | 12.85M | 19.47M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 32.58M | 7.90M | 1.08M | 10.51M | 143.89M | 174.00K | 66.73M | 8.58M | 25.41M | 12.85M | 19.47M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 87.56M | 61.62M | 59.82M | 43.15M | 30.22M | 36.98M | 28.89M | 27.47M | 21.79M | 24.19M | 23.44M |
| General & Administrative | 22.25M | 18.62M | 19.97M | 22.94M | 21.02M | 14.36M | 13.06M | 11.70M | 8.03M | 7.27M | 7.38M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.25M | 18.62M | 19.97M | 22.94M | 21.02M | 14.36M | 13.06M | 11.70M | 8.03M | 7.27M | 7.38M |
| Other Expenses | 283.00K | 301.00K | 306.00K | 0.00 | 0.00 | 0.00 | 0.00 | 20.90M | 12.84M | 0.00 | 0.00 |
| Operating Expenses | 110.09M | 80.55M | 80.09M | 66.09M | 51.24M | 51.34M | 41.94M | 39.17M | 29.82M | 31.46M | 30.81M |
| Cost & Expenses | 110.09M | 80.55M | 80.09M | 66.09M | 51.24M | 51.34M | 41.94M | 39.17M | 29.82M | 31.46M | 30.81M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | -127.00K | 815.00K | 447.00K | 309.00K | 1.15M | 1.67M | 1.86M | 18.00K |
| Depreciation & Amortization | 4.02M | 3.81M | 827.00K | 1.25M | 1.01M | 893.00K | 785.00K | 1.05M | 1.35M | 1.45M | 1.62M |
| EBITDA | -73.49M | -68.84M | -78.19M | -54.46M | 97.16M | -49.83M | 25.70M | -29.50M | -3.04M | -17.14M | -9.68M |
| EBITDA Ratio | -225.57% | -871.15% | -7,259.80% | -518.46% | 67.52% | -28,636.21% | 38.51% | -343.95% | -11.98% | -133.36% | -49.74% |
| Operating Income | -77.51M | -72.65M | -79.02M | -55.58M | 92.65M | -51.17M | 24.79M | -30.60M | -4.41M | -18.61M | -11.35M |
| Operating Income Ratio | -237.92% | -919.35% | -7,336.58% | -529.12% | 64.39% | -29,406.32% | 37.15% | -356.79% | -17.36% | -144.84% | -58.28% |
| Total Other Income/Expenses | -2.54M | -2.20M | 849.00K | -127.00K | 2.69M | 447.00K | -185.00K | -1.10M | -1.65M | -1.83M | 26.00K |
| Income Before Tax | -80.05M | -74.85M | -78.17M | -55.71M | 95.34M | -50.72M | 24.60M | -31.70M | -6.06M | -20.44M | -11.32M |
| Income Before Tax Ratio | -245.72% | -947.24% | -7,257.75% | -530.33% | 66.26% | -29,149.43% | 36.87% | -369.62% | -23.84% | -159.11% | -58.15% |
| Income Tax Expense | 2.54M | -85.00K | -837.00K | 313.00K | -300.00K | 447.00K | 429.00K | 49.00K | 21.00K | 22.00K | 44.00K |
| Net Income | -82.59M | -74.77M | -77.33M | -56.02M | 95.64M | -50.72M | 24.17M | -31.70M | -6.06M | -20.44M | -11.32M |
| Net Income Ratio | -253.53% | -946.17% | -7,180.04% | -533.31% | 66.47% | -29,149.43% | 36.23% | -369.62% | -23.84% | -159.11% | -58.15% |
| EPS | -2.40 | -2.40 | -3.26 | -2.40 | 4.22 | -2.28 | 1.14 | -2.00 | -0.35 | -1.82 | -1.01 |
| EPS Diluted | -2.40 | -2.40 | -3.26 | -2.40 | 4.08 | -2.28 | 1.09 | -2.00 | -0.35 | -1.82 | -1.01 |
| Weighted Avg Shares Out | 34.41M | 31.20M | 23.74M | 23.37M | 22.64M | 22.23M | 21.15M | 15.84M | 17.22M | 11.21M | 11.21M |
| Weighted Avg Shares Out (Dil) | 34.41M | 31.20M | 23.74M | 23.37M | 23.44M | 22.23M | 22.27M | 15.84M | 17.22M | 11.21M | 11.21M |
Concert Pharmaceuticals: A Balanced Risk/Reward
Concert Pharmaceuticals has a JAK inhibitor for alopecia areata (AA) that may be superior to competitive products. The company cites a figure of 1.5m US patients with AA. Published literature cites a prevalence of 700,000 patients and only 300,000 with...
Concert Pharmaceuticals to Participate in Fireside Chat at The JMP Securities Life Sciences Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at The JMP Securities Life Sciences Conference on June 16, 2022 at 1:00 p.m. ET in New York, NY. A webcast of the...
Concert Pharmaceuticals to Participate in Fireside Chat at The JMP Securities Life Sciences Conference
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at The JMP Securities Life Sciences Conference on June 16, 2022 at 1:00 p.m. ET in New York, NY. A webcast...
Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of the American Academy of Dermatology
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the publication of safety and efficacy data from the randomized, double-blind, placebo-controlled dose-ranging Phase 2 clinical trial for CTP‑543 in the Journal of the American Academy of Dermatology (JAAD). CTP-543 is...
Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of the American Academy of Dermatology
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--CTP-543 Phase 2 results in alopecia areata published in JAAD.
Concert Pharmaceuticals Raises Gross Proceeds of $66.4 Million Through Public Offering and Exercise of Warrants
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the closing of its previously announced underwritten public offering of 10,000,000 shares of its common stock to the public at $4.75 per share. The aggregate gross proceeds to Concert from this...
Concert Pharmaceuticals Raises Gross Proceeds of $66.4 Million Through Public Offering and Exercise of Warrants
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the closing of its previously announced underwritten public offering of 10,000,000 shares of its common stock to the public at $4.75 per share. The aggregate gross proceeds to Concert from this...
Concert Pharmaceuticals Announces Pricing of Public Offering
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals announces pricing of public offering.
Concert Pharmaceuticals Announces Pricing of Public Offering
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $4.75 per share. The gross proceeds to Concert, before deducting underwriting...
Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it intends to offer and sell 10,000,000 shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by...
Source: https://incomestatements.info
Category: Stock Reports